[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intoxication-by-drug\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intoxication-by-drug":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,77],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100444435","phase-1-evaluation-of-oral-thc-and-cbd-in-men-and-women-100444435",false,"NCT05067387","Evaluation of Oral THC and CBD in Men and Women","Evaluation of Oral THC and CBD in Oral Fluid, Pharmacokinetics, and Subjective and Neurocognitive Effects in Men and Women","O-TACOFS","Inclusion Criteria:\n\n* Male or non-pregnant and non-lactating females aged 21-55 years\n* Report weekly-monthly use of cannabis (≤1 day per week) over the past month prior to screening,\n* Not currently seeking treatment for their cannabis use\n* Have a Body Mass Index from 18.5 - 34kg\u002Fm2.\n* Able to perform all study procedures\n* Must be using a contraceptive (hormonal or barrier methods)\n\nExclusion Criteria:\n\n* Meeting DSM-V criteria for moderate to severe Cannabis Use disorder (CUD) or any substance use disorder other than nicotine, caffeine\n* Any other Axis I disorder\n* Report using other illicit drugs in the prior 4 weeks, other than cannabis.\n* Current use of any medications that may affect study outcomes\n* If medical history, physical and psychiatric examination, or laboratory tests performed during the screening process are not within the normal range and \u002F or reveal any significant illness (e.g., hypertension) as judged by the study physician and to put the participant at greater risk of experiencing adverse events due to completion of study procedures.\n* Pregnancy is exclusionary due to the possible effects of the study medication on fetal development.\n* History of an allergic reaction or adverse reaction to cannabis is exclusionary.\n* History of respiratory illness or current respiratory illness\n* Currently enrolled in another research protocol\n* Not using a contraceptive method (hormonal or barrier methods)\n* The evaluating physician reviews all medical assessments along with medical history. Any disorders that might make cannabis administration hazardous are exclusionary.",true,"ALL","21 Years","55 Years",{"count":22,"type":23},22,"ESTIMATED","INTERVENTIONAL",[26],"PHASE1","The purpose of this study is to determine the pharmacokinetics and pharmacodynamics of oral delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and to evaluate detection of recently smoked THC in oral fluid.",[29,30,31],"Drug Abuse","Intoxication by Drug","Impairment",[33,34,35,31],"THC","CBD","Intoxication","NOT_YET_RECRUITING","2026-06-09",{"date":39,"type":40},"2026-06-11","ACTUAL",{"date":42,"type":23},"2026-07-15",{"date":44,"type":23},"2028-06-15",{"name":46,"class":47},"University of California, Los Angeles","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":24,"phases":59,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":48},"100587007","hemadsorption-to-enhance-drug-elimination-in-intoxications-100587007","NCT06922786","Hemadsorption to Enhance Drug Elimination in Intoxications","MATRIX","Inclusion Criteria:\n\n1. older than18 years\n2. Admission to ICU\n3. GCS \\\u003C 8 or requiring Flumazenil 8 hours after hospital admission\n4. Having an intoxication with a benzodiazepine or tricyclic antidepressant that we can measure\u002Fquantify\n5. Having a risk factor for delayed drug elimination defined as either Cirrhosis CHILD B\u002FC or chronic kidney insufficiency KDIGO 3b or worse\n\nExclusion Criteria:\n\n1. Pregnant patient\n2. Patients in chronic dialysis before admission\n3. Need for mechanical ventilation for other reasons than intoxications (e.g. pneumonia, neurotrauma)\n4. Concomitant pathology requiring continued intravenous sedation\n5. Known history of seizures\n6. Contra-indication to heparin use\n7. DNR restricting the use of mechanical ventilation or dialysis","18 Years",{"count":58,"type":23},18,[60],"NA","In this trial the investigators assess the effectiveness of applying a hemadsorber (cytosorb®) in removing benzodiazepines or tricyclic antidepressants in intoxicated patients admitted to ICU with prolonged impaired consciousness. This is a one arm interventional investigation where a hemadsorption filter is applied in patients fulfilling inclusion criteria 8 hours after admission. Plasma titer of the neurodepressing drug will be collected sequentially both before and after start of hemadsorption to evaluate the speed of drug elimination before and after application of a hemadsorption filter. Pre- and post filter titers will be obtained to evaluate adsorbability and to evaluate time to saturation of the filter.",[30],[64,65,35,66],"Benzodiazepine","Tricyclic antidepressant","Hemadsorption","RECRUITING","2025-05-12",{"date":70,"type":40},"2025-05-15",{"date":72,"type":23},"2025-05",{"date":74,"type":23},"2029-01",{"name":76,"class":47},"Universitair Ziekenhuis Brussel",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":85,"targetDuration":87,"studyType":88,"phases":4,"briefSummary":89,"conditions":90,"keywords":109,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":48},"100409713","acutelines-a-large-data-biobank-of-acute-and-emergency-medicine-100409713","NCT04615065","Acutelines: a Large Data-\u002FBiobank of Acute and Emergency Medicine","Acutelines: a Large Biobank Aiming to Improve Early Recognition of Acute Diseases, Contribute to the Development of Personalized Medicine and Optimize Short- and Long-term Outcome","Acutelines","Inclusion Criteria, at least one of the following:\n\n* Triaged as one of highest two triage categories (red or orange) according to the Manchester triage system;\n* Triaged as the third highest triage category (yellow) and arrival by EMS of Helicopter Emergency Medical Service (HEMS;\n* Shock\n* Suspicion of sepsis (based on either physicians' suspicion, Sepsis-2 or Sepsis-3 criteria)\n* Acute kidney injury (AKI)\n* Anaphylactic reaction\n* Syncope\n* Intoxication\n* Thrombosis\n* Pulmonary embolism\n* Bleeding while using anti-coagulant drugs\n* Gastro-intestinal bleeding\n* Electrolyte disturbance\n\nExclusion Criteria:\n\n* Referred for organ transplantation as recipient\n* Transfer from other hospital\n* Accidental contact patient material (i.e. internal work-related accident)\n\nWhile data- and imaging will be collected from all these patients, biomaterials will only be collected from patients fulfilling the first criterion (i.e. triaged as one of highest two triage categories \\[red or orange\\] according to the Manchester triage system) and from patients with shock or a suspicion of sepsis.",{"count":86,"type":23},35000,"5 Years","OBSERVATIONAL","Research in acute care faces many challenges, including enrollment challenges, legal limitations in data sharing, limited funding, and lack of singular ownership of the domain of acute care. To overcome some of these challenges, the Center of Acute Care of the University Medical Center Groningen in the Netherlands, has established a de novo data-, image- and biobank named \"Acutelines\". Acutelines is initiated to improve recognition and treatment of acute diseases and obtain insight in the consequences of acute diseases, including factors predicting its outcome. Thereby, Acutelines contributes to development of personalized treatment and improves prediction of patient outcomes after an acute admission.",[91,92,93,94,95,96,97,98,99,100,101,102,30,103,104,105,106,107,108],"Acute Disease","Sepsis","Pneumonia","Frailty","Complication of Treatment","Pulmonary Embolism","Thrombosis","Acute Kidney Injury","Electrolyte Disturbance","Hemorrhage","Shock","Polypharmacy","Emergencies","Urinary Tract Infections","Skin Infection","Syncope","Anaphylaxis","Dyspnea",[110,92,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131],"Acute disease","Emergency Medical Service (EMS)","Outcome","Precision medicine","Personalized medicine","Emergency medicine","Multidisciplinary","General practitionar","Pharmacy","Hospitalization","Health insurance","Mortality","Quality of life (QoL)","Overcrowding","Patient logistics","Point-of-care ultrasound (POCUS)","Helicopter Emergency Medical Service (HEMS)","Biobank","Databank","Electrophysiological waveforms","Electrocardiogram (ECG)","Plethysmogram","2024-06-12",{"date":134,"type":40},"2024-06-13",{"date":136,"type":40},"2020-09-01",{"date":138,"type":23},"2030-09-01",{"name":140,"class":47},"University Medical Center Groningen"]